Core Laboratories NV (NYSE:CLB) shares dropped 3.2% during mid-day trading on Thursday . The stock traded as low as $119.92 and last traded at $119.92, with a volume of 389,252 shares. The stock had previously closed at $123.87.

CLB has been the topic of several analyst reports. ABN Amro downgraded shares of Core Laboratories NV from a “buy” rating to a “sell” rating in a research note on Friday, April 22nd. Morgan Stanley increased their price objective on shares of Core Laboratories NV from $120.00 to $140.00 and gave the company an “overweight” rating in a research report on Tuesday, April 19th. Stephens assumed coverage on shares of Core Laboratories NV in a research report on Tuesday, April 5th. They set an “equal weight” rating and a $89.00 price objective on the stock. Citigroup Inc. increased their price objective on shares of Core Laboratories NV from $115.00 to $123.00 and gave the company a “neutral” rating in a research report on Monday, May 16th. Finally, Howard Weil increased their price objective on shares of Core Laboratories NV to $112.00 in a research report on Monday, March 28th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $121.00.

The firm’s 50-day moving average is $123.20 and its 200-day moving average is $113.57. The company has a market capitalization of $5.16 billion and a P/E ratio of 62.98.

Core Laboratories NV (NYSE:CLB) last announced its quarterly earnings data on Wednesday, July 20th. The company reported $0.35 EPS for the quarter, meeting the consensus estimate of $0.35. The business had revenue of $148.10 million for the quarter, compared to analyst estimates of $146.37 million. During the same quarter in the previous year, the firm posted $0.81 earnings per share. The business’s revenue was down 27.4% on a year-over-year basis. Equities analysts predict that Core Laboratories NV will post $1.62 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 15th. Shareholders of record on Monday, July 18th will be paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 1.85%. The ex-dividend date of this dividend is Thursday, July 14th.

A number of hedge funds have made changes to their positions in the stock. Poplar Forest Capital LLC boosted its stake in shares of Core Laboratories NV by 2.7% in the fourth quarter. Poplar Forest Capital LLC now owns 9,650 shares of the company’s stock valued at $1,049,000 after buying an additional 250 shares during the last quarter. WCM Investment Management CA boosted its stake in shares of Core Laboratories NV by 44.5% in the fourth quarter. WCM Investment Management CA now owns 3,188,453 shares of the company’s stock valued at $346,713,000 after buying an additional 981,243 shares during the last quarter. Aberdeen Asset Management PLC UK acquired a new stake in shares of Core Laboratories NV during the fourth quarter valued at approximately $5,554,000. Howland Capital Management LLC boosted its stake in shares of Core Laboratories NV by 4.7% in the fourth quarter. Howland Capital Management LLC now owns 102,070 shares of the company’s stock valued at $11,099,000 after buying an additional 4,562 shares during the last quarter. Finally, Ameritas Investment Partners Inc. acquired a new stake in shares of Core Laboratories NV during the fourth quarter valued at approximately $1,043,000.

Core Laboratories N.V. is a provider of reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company’s services and products are directed toward enabling the Company’s clients to improve reservoir performance and increase oil and gas recovery from their producing fields.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.